Isocarboxazid 2171835 207995821 2008-04-25T00:04:36Z Chowbok 54304 clean up, Replaced: ® → (3) using [[Project:AutoWikiBrowser|AWB]] {{Drugbox| |IUPAC_name = ''N'-benzyl-5-methyl-oxazole-3-carbohydrazide'' | image=Isocarboxazid structure.svg | width=100 | CAS_number=59-63-2 | ATC_prefix=N06 | ATC_suffix=AF01 | ATC_supplemental= | PubChem=3759 | DrugBank=APRD00701 | C = 12 | H = 13 | N = 3 | O = 2 | molecular_weight = 231.26 | bioavailability= ? | metabolism = [[Liver]] | elimination_half-life= ? | excretion = [[Urine]] | pregnancy_category = C ([[United States|USA]]) | legal_status = Rx-only | routes_of_administration= Oral }} '''Isocarboxazid''' is a nonselective [[hydrazine]]-derived [[monoamine oxidase inhibitor]] used in treatment resistant [[clinical depression|depression]]. ==Uses== ===Approved=== In the United States, isocarboxazid is approved for the treatment of depression, anxiety (panic disorder) with or without agoraphobia. In the United Kingdom, isocarboxazid is licensed for the treatment of depression unresponsive to selective serotonin reuptake inhibitors (SSRIs). ===Off-Label/Unapproved/Investigational=== A [[randomized controlled trial]] published in December of 1988 found that isocarboxazid significantly reduced [[binge]]ing and [[purging]] in [[bulimia nervosa]], regardless of the presence or absence of depression or [[personality disorder]].{{ref|bulimia}} ==Brand Names== ===United States=== '''MARPLAN''' by [[Hoffmann-La Roche]], starting in [[1959]] and discontinuing in [[1994]]. After much patient and physician outcry, they resumed manufacturing just enough '''Marplan''' to distribute on an as-needed basis. In October of [[1998]], Hoffmann-La Roche and [[Oxford Pharmaceutical Services|Oxford Pharmaceutical Services Inc.]] announced that Oxford, "is acquiring ownership of the [[NDA]] for the [[antidepressant]] product Marplan (isocarboxazid) from Roche."{{ref|marplanpressrelease}} The maximum daily dose of isocarboxazid is 60mg. ===United Kingdom=== Isocarboxazid is availably generically in the United Kingdom in the form of 10mg tablets. However, it is considered 'less suitable for prescribing' by the British National Formulary (BNF). ==References== * [http://www.drugs.com/cons/Isocarboxazid.html drugs.com Isocarboxazid Drug Information] * [http://www.intox.org/databank/documents/pharm/maoi/pimg025.htm Monoamine-oxidase inhibitors (Group PIM G025)] IPCS INTOX Databank * [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=39705 PubChem Substance Summary: Isocarboxazid] National Center for Biotechnology Information. # {{note|bulimia}} Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE. "A trial of isocarboxazid in the treatment of bulimia nervosa." ''Journal of Clinical Psychopharmacology.'' 1988 Dec;8(6):391-6. PMID 3069879 # {{note|marplanpressrelease}} [http://www.oxfordpharm.com/Press%20Release.htm Marplan Press Release] Oxford Pharmaceutical Services. {{Antidepressants}} [[Category:Monoamine oxidase inhibitors]] [[Category:Hydrazines]] [[Category:Isoxazoles]]